---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-002928"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T21:56:39.699875+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oragenics appoints CFO Janet Huffman as interim CEO; provides ONP-002 Phase II timeline

## Summary
- CFO Janet Huffman named interim CEO, retaining CFO role; board expresses confidence in her leadership.
- Company raised $4M in September 2024; progress includes improved ONP-002 formulation and device prototyping.
- Phase II trial in Australia: first patient dosing targeted by end of Q1 2025 or early Q2 2025.
- IND package for U.S. Phase IIb clinical trial targeted for Q3 2025.
- Spray-dry campaign completed to ensure sufficient drug-device units for upcoming trials.

## SEC filing metadata
- accession: 0001493152-25-002928
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315225002928/0001493152-25-002928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315225002928/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-002928
- JSON: https://secwatch.observer/filing/0001493152-25-002928.json
- Plain text: https://secwatch.observer/filing/0001493152-25-002928.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.